Response to pembrolizumab in lung squamous cell carcinoma with PD-L1 overexpression and EGFR rare mutation: a case report

The goal of this study was to investigate whether the low response rate to PD-1/PD-L1 inhibitors is different between EGFR common mutation and rare mutation in NSCLC patients. Methods: The patient was treated with Pembrolizumab monotherapy for three cycles in third line therapy. Results: a metastatic lung squamous cell cancer with EGFR V843I mutation and PD-L1 overexpression was evaluated as PR. Conclusion: this is the first case report of response to PD-L1 inhibitors for a lung squamous cell carcinoma patient with PD-L1 overexpression and EGFR rare mutation, which helps future immunity therapy for patients with EGFR rare variants in NSCLC.